Ignite Creation Date:
2024-05-06 @ 2:54 AM
Last Modification Date:
2024-10-26 @ 11:25 AM
Study NCT ID:
NCT02156297
Status:
UNKNOWN
Last Update Posted:
2020-02-05
First Post:
2014-05-30
Brief Title:
Sorafenib to Treat FLT3-ITD AML
Sponsor:
The First Affiliated Hospital of Soochow University
Organization:
The First Affiliated Hospital of Soochow University
Study Overview
Official Title:
Sorafenib to Treat AML Patients With FLT3-ITD Mutation a Non-interventional Cohort Study
Status:
UNKNOWN
Status Verified Date:
2020-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is a prospective non-interventional open-label study in order to observe the safety and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as induction consolidation salvage maintenance or alleviative treatment The duration of the study from June 2014 through May 2019 with the recruitment duration from June 2014 to May 2017 The inclusion criteria is
1 Definitely diagnosed as AML
2 FLT3-ITD mutation has been confirmed
3 Accepting the prescription of sorafenib
1 Definitely diagnosed as AML
2 FLT3-ITD mutation has been confirmed
3 Accepting the prescription of sorafenib
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None